C-Trend®

Introducing a new method for practical brain monitoring

CERENION C-TREND® offers the first truly objective and practical method to obtain reliable information on the condition and function of the brain. The clinically validated measure can be integrated into EEG-measurement devices and patient monitors as a software feature.
CERENION C-TREND® is a CE-marked medical-grade software solution that works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The result is a simple index that measures the condition and function of the brain on a scale from 0 to 100.
The technology has the potential of improving both the quality and the cost of intensive care.

What is C-Trend®?

C-Trend® technology is not available in the US.

C-Trend® Index

C-Trend® software utilizes artificial intelligence to process the complex EEG signal into one simple score, the C-Trend® Index. The index describes the EEG slow-wave activity (<1 Hz) as a single parameter ranging from 0 to 100. Slow-wave activity is a neurophysiological feature that is highly important for healthy brain function occurring during sedation and natural sleep.
C-Trend® Index is intended to aid in the monitoring of the neurophysiological status of sedated patients. These patients include comatose cardiac arrest survivors.

C-Trend® in predicting the outcome after cardiac arrest

C-Trend® technology is not available in the US.

Other parameters

In addition to C-Trend Index, C-Trend software provides calculation of three conventional parameters: Burst Suppression Ratio (BSR), Amplitude-Integrated EEG (aEEG), and Alpha-Delta Ratio (ADR). This set of parameters allows C-Trend to be used in a wide variety of conditions in intensive care including:
-Treatment of status epilepticus with deep anesthesia
-Non-convulsive status epilepticus
-Delayed cerebral ischemia after subarachnoid hemorrhage

Scientific & Clinical validation

We have our roots in academic research and understand the importance of extensive scientific validation of any new technology. We are located at the heart of the internationally recognized Oulu Health ecosystem in Finland, and have formed close collaboration ties with the University of Oulu and the Oulu University Hospital. Through this work we continue to innovate and test our technology, and also invite others to join in.
We place great value in publishing our findings on high-quality scientific forums, and also wish to help others test out and build on our work. As a part of this, we are engaged in running clinical multisite studies.
"There are currently no reliable methods for assessing brain function in the early stages of recovery from hypoxic, ischemic, or traumatic insults that might inform neurologic prognosis and therapy. Slow electroencephalographic waves induced by general anesthetics might provide a neurophysiologic signature of healthy brain function."
Hugh C. Hemmings, M.D., Ph.D., Handling Editor, Anesthesiology in regards to our scientific publication in the journal
"Outstanding example of research."
Professor Esa Mervaala, Council Chair, Vaajasalo Foundation in regards to our scientific publication recognized at NCCN & KES 2017
"This invention will ease the day-to-day work at intensive care units"
Associate Chief Physician of Intensive Care, Dr. Jouko Laurila in newspapers Kaleva, Aamulehti, Turun Sanomat, Lapin Kansa, Forssan Lehti, Ilkka and Pohjalainen
"The technology Cerenion is developing has great potential in helping EEG specialists in faster and more accurate interpretation of EEG"
Chief Physician of Clinical Neurophysiology, Dr. Mika Kallio
Visit us
OULU
Cerenion Oy
Elektroniikkatie 3
90590 Oulu
FINLAND
HELSINKI
Cerenion Oy
Kyllikinportti 2
00240 Helsinki
FINLAND
Contact us
Call us: +358 50 447 4909
E-mail us:
Cerenion Oy has received support from the European Regional Development Fund of the European Union.
This website and all of the content therein is for reference purposes only and is not intended to substitute for advice from a licensed healthcare professional. Not available in the United States. Cerenion™, Cerenion C-Trend™, C-Trend™, "The next-generation brain monitoring company"™ and "The pulse of the brain"™ are registered trademarks and/or trademarks of Cerenion Oy. Cerenion C-Trend™ is intended for use by qualified medical practitioners who will exercise professional judgment in its use. Cerenion technology is protected by Intellectual Property Rights. Patents pending worldwide. All rights reserved. © Cerenion Oy 2020.
Powered by:MetaVisual CMSMobile versionDesktop versionLog in© 2017 - 2024 Cerenion Oy